Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 7/20 | 0.58 |
| ▸ | JAK2 | O60674 | 4/20 | 0.58 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.58 |
| ▸ | AURKA | O14965 | 3/20 | 0.58 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.58 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.58 |
| ▸ | FLT1 | P17948 | 3/20 | 0.58 |
| ▸ | KDR | P35968 | 3/20 | 0.58 |
| ▸ | CLK2 | P49760 | 3/20 | 0.58 |
| ▸ | MAP4K2 | Q12851 | 3/20 | 0.58 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.58 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.58 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.58 |
| ▸ | TAOK1 | Q7L7X3 | 2/20 | 0.58 |
| ▸ | IGF1R | P08069 | 2/20 | 0.58 |
| ▸ | JAK3 | P52333 | 2/20 | 0.58 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.58 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.58 |
| ▸ | PLK4 | O00444 | 1/20 | 0.58 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL27874537 | 0.98 | DYRK1A (0.57) | DYRK1AJAK2CDK5AURKAMAP4K4 | |
| SCHEMBL15241762 | 0.80 | BRD4 (0.49) | DYRK1AJAK2CDK5AURKAMAP4K4 | |
| Valine SCHEMBL18860660 | 0.80 | DYRK1A (0.44) | DYRK1AJAK2CDK5AURKAMAP4K4 | |
| SCHEMBL1880862 | 0.77 | BRD4 (0.47) | DYRK1AMAP4K4CLK2CLK4ROCK2 | |
| SCHEMBL1053943 | 0.77 | JAK2 (0.58) | JAK2FLT1KDRAURKBFLT3 | |
| SCHEMBL11968454 | 0.77 | BRD4 (0.47) | DYRK1AJAK2CDK5AURKAMAP4K4 | |
| SCHEMBL1045946 | 0.77 | BRD4 (0.54) | DYRK1AJAK2CDK5AURKAMAP4K4 | |
| SCHEMBL1564760 | 0.77 | ITK (0.54) | DYRK1AJAK2CDK5AURKAMAP4K4 | |
| SCHEMBL1564507 | 0.77 | GSK3B (0.56) | DYRK1AJAK2CDK5AURKAMAP4K4 | |
| SCHEMBL11968456 | 0.77 | DYRK1A (0.54) | DYRK1AJAK2CDK5AURKAMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 297 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117466889-A | 1H-pyrrole [2,3-b ] pyridine compound and synthetic method and application thereof | 杭州医学院 | 2024-01-30 | — | — | CN | claimed |
| US-10995089-B2 | Zaindole derivatives and their use as ERK kinase inhibitors | AGV DISCOVERY (FR) | 2021-05-04 | — | — | US | claimed |
| US-20200283432-A1 | ZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV Discovery ENSCM (FR) | 2020-09-10 | — | — | US | claimed |
| EP-3377491-B1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV DISCOVERY (FR) | 2019-11-13 | — | — | EP | claimed |
| EP-3377491-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV Discovery (FR) | 2018-09-26 | — | — | EP | claimed |
| EP-3170822-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV Discovery (FR) | 2017-05-24 | — | — | EP | claimed |
| EP-4688778-A1 | 1H-PYRROLO[2,3-B]PYRIDIN-4-YL]-2-OXOPYRROLIDINE-3-CARBONITRILE DERIVATIVES AS TYROSINE KINASE 2 (TYK2) INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | Biogen MA Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20250388571-A1 | AMP-ACTIVATED PROTEIN KINASE MODULATOR COMPOUNDS AND USES THEREOF | BIOLEXIS THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12459958-B2 | Tricyclic compounds as HPK1 inhibitor and the use thereof | BEONE MEDICINES I GMBH (CH) | 2025-11-04 | — | — | US | disclosed |
| EP-4628489-A1 | 7-AZAINDOLE COMPOUNDS, PREPARATION METHOD THEREFOR, AND USE THEREOF | Fudan University (CN) | 2025-10-08 | — | — | EP | disclosed |
| EP-4340833-B1 | NOVEL AZAINDOLE DERIVATIVES AS ANTIVIRAL AGENTS | CENTRE NAT RECH SCIENT (FR) | 2025-09-03 | — | — | EP | disclosed |
| US-20250195516-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2025-06-19 | — | — | US | disclosed |
| CN-116143779-B | Compound of hematopoietic progenitor cell kinase 1 inhibitor, preparation method and application thereof | 中国药科大学 | 2025-06-13 | — | — | CN | disclosed |
| US-20070043068-A1 | to treat diseases mediated by kinase activity; for example: [3-(2-methoxy-phenyl)-1H-pyrrolo[2,3-b]pyridine-5-yl]-methyl-phenyl-amine | SGX PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20060270646-A1 | Jnk inhibitors | EISAI CO., LTD. (JP) | 2006-11-30 | — | — | US | disclosed |
| US-20060030583-A1 | Pyrrolo-pyridine kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2006-02-09 | — | — | US | disclosed |
| WO-2006015123-A1 | PYRROLO-PYRIDINE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| EP-1599475-A2 | JNK INHIBITORS | Eisai Co., Ltd. (JP) | 2005-11-30 | — | — | EP | disclosed |
| WO-2004078756-A2 | JNK INHIBITORS | EISAI CO., LTD. (JP) | 2004-09-16 | — | — | WO | disclosed |
| WO-2004078756-A2 | JNK INHIBITORS | EISAI CO., LTD. (JP) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10995089-B2 | Zaindole derivatives and their use as ERK kinase inhibitors | MAPKAPK2, MAPK1, MAPK3 | DYRK1A 595/4885JAK2 203/4885CDK5 135/4885 |
| US-20250388571-A1 | AMP-ACTIVATED PROTEIN KINASE MODULATOR COMPOUNDS AND USES THEREOF | PRKAB2, PRKAB1, PRKAR2B | DYRK1A 549/4885JAK2 877/4885CDK5 754/4885 |
| US-20060030583-A1 | Pyrrolo-pyridine kinase modulators | MAP3K20, MAP4K2, MAP3K19 | DYRK1A 261/4885JAK2 291/4885CDK5 205/4885 |
| US-20060270646-A1 | Jnk inhibitors | MAPKAPK2, MAPK1, MAPKAPK3 | DYRK1A 1609/4885JAK2 777/4885CDK5 52/4885 |
| US-20250195516-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, PRKACA, MAP3K13 | DYRK1A 638/4885JAK2 250/4885CDK5 164/4885 |
| US-20200283432-A1 | ZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | MAPKAPK2, MAPK1, MAPK3 | DYRK1A 595/4885JAK2 203/4885CDK5 135/4885 |
| US-20070043068-A1 | to treat diseases mediated by kinase activity; for example: [3-(2-methoxy-phenyl)-1H-pyrrolo[2,3-b]pyridine-5-yl]-methyl-phenyl-amine | MAP3K20, MAP4K2, MAP3K6 | DYRK1A 673/4885JAK2 113/4885CDK5 288/4885 |
| US-12459958-B2 | Tricyclic compounds as HPK1 inhibitor and the use thereof | ULK1, SBK1, PHKG1 | DYRK1A 1319/4885JAK2 2099/4885CDK5 890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.